📰 Human Use News
Page 118 - Human Use News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Human Use. Real-time updates on events, politics, business and more.
September 1, 2022
CHMP recommendation based on safety, tolerability, and immunogenicity data from a Phase 2/3 trial of the Omicron BA.1-adapted bivalent vaccineThe Omicron BA.1-adapted bivalent COVID-19 vaccine combines
September 1, 2022
/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious...
September 1, 2022
/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious...
August 31, 2022
It is estimated that every year more than 6,300 people will be diagnosed with CML in Europe - News - PharmaTimes
August 31, 2022
Therapy is a biosimilar of Lucentis which treats several serious retinal diseases across the European Union - News - PharmaTimes
August 30, 2022
(RTTNews) - Novartis (NVS) said that the European Commission has approved Scemblix (asciminib) for the treatment of adult patients with Philadelph...
August 30, 2022
Teva announced today that the European Commission has granted marketing authorization for RANIVISIO, a biosimilar ranibizumab, for the treatment of age-related macular degeneration...
August 30, 2022
Polpharma Biologics Group BV (“Polpharma Biologics”), Formycon AG (“Formycon”) and Bioeq AG (“Bioeq”) jointly announce that the European Commission (“EC”) has granted marketing authorization (“MA”) to Ranivisio® (Ranivisio - Ranibizumab), a biosimilar to Lucentis® (ranibizumab-injection), for the treatment for ...
August 30, 2022
Novartis Scemblix®, with novel mechanism of action, approved by the European Commission for adult patients with chronic myeloid leukemia
August 30, 2022
The European Commission (EC) has approved Novartis’ Scemblix (asciminib) to treat chronic myeloid leukemia (CML) in adult patients.